Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—
Dec '25
Current Ratio
17.03
Net Debt/EBITDA
1.34
Debt/Assets
0.00%
Debt/Equity
0.00
Operating CF/Net income
0.03
ROE
0.00%
ROA
0.00%
ROIC
0.00%
Return on Tangible Assets
(78.60%)
Research and Development Expense of Revenue
0.00%
Selling, General and Administrative Expense of Revenue
0.00%
Intangible Assets out of Total Assets
0.00
Share Based Compensation of Revenue
0.00%
Free Cash Flow per Share
(0.52)
Cash per Share
23.22
Shareholders Equity per Share
(17.15)
Interest Debt per Share
0.00
Book value per Share
(17.15)
Free Cash Flow
(2.01)
Working Capital
84.04
Net Current Asset Value
(65.94)
Other line items
Quick Ratio
17.01
Cash ROIC
(8.65%)
Average Days of Payables
0.00
Revenue per Share
0.00
Operating CF per Share
(0.52)
Capex per Share
0.00

Fold the line items

Columns are period end dates · fundamentals updated 12 Nov 2026